Cell & Gene Therapy Trials: The Need for Flexibility (Chapter 2 of 5)

Adam Callahan, Caidya’s Vice President of Clinical Development and Therapeutic Area Head for Hematology-Oncology, explains why cell and gene therapies are often grouped together despite important therapeutic differences. He discusses how cell therapy patients may serve as their own donors, while gene therapy involves manipulating the genome and presents a different patient risk profile. The conversation also examines the logistical complexity of collecting, processing, and later administering a therapy. Adam highlights why flexibility and adaptability are critical when managing these trials and how experienced development and operational teams can help address their distinct requirements.